Affiliated Hospital of Hebei University
25
2
3
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
4.0%
1 terminated/withdrawn out of 25 trials
87.5%
+1.0% vs industry average
8%
2 trials in Phase 3/4
0%
0 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (25)
AI-Assisted Staging and Treatment Decision-Making for Hepatocellular Carcinoma
Role: collaborator
Dexmedetomidine Supplemented Analgesia and Incidence of Postoperative Delirium
Role: collaborator
Dexmedetomidine Supplemented Analgesia and Long-term Survival After Cancer Surgery
Role: collaborator
Romiplostim N01 in the Treatment of Thrombocytopenia Caused by Cytotoxic Drugs in Breast Cancer Patients
Role: collaborator
Effect of Acupuncture and Herbal Medicine on Bowel Recovery After Abdominal Surgery
Role: collaborator
Effect of Premedication With Pronase on Mucosal Cleanliness During EGD
Role: collaborator
A Clinical Diagnostic System for Intrinsic Acute Kidney Disease
Role: collaborator
Evaluation of Two Different Treatments for Lower Pore Renal Stone: Microperc Vs FURS
Role: collaborator
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
Role: collaborator
Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.
Role: collaborator
Chinese Cohort Study of Chronic Kidney Disease
Role: collaborator
Tissue Predictors of Abiraterone Benefit
Role: collaborator
Effect of Concurrent Capecitabine-based Long-term Radiotherapy Followed by XELOX Plus TME in Patients With High Risk Rectal Cancer: a Multi-centers, Randomized Controlled, Open-Label Trial
Role: collaborator
Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
Role: collaborator
Study of Efficacy, Safety, and Pharmacokinetics of FCN-437c in Combination With Fulvestrant or Letrozole+Goserelin
Role: collaborator
Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01
Role: collaborator
Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma
Role: collaborator
Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02
Role: collaborator
Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01
Role: collaborator
Circulating Tumor DNA Longitudinal Monitoring in Stage III-IV Lung Cancer Patients
Role: collaborator